source
- AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purificationThe industry is moving from ex vivo to in vivo gene delivery, a change that forces viral vector manufacturers to rethink scale, purity, cell lines and analytical methods. In in vivo approaches the…
- BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunityThe FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach. Since its launch, the drug ha…